14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

$0.0135 (-10.69%)

Volume: 816.437k

Closed: Sep 26, 2022

Hollow Logo Score: 1.190

Genocea Biosciences Stock Forecast

$0.0135 (-10.69%)

Volume: 816.437k

Closed: Sep 26, 2022

Score Hollow Logo 1.190

Genocea Biosciences Stock News NASDAQ:GNCA

Upgrades Fox Advisors upgraded the previous rating for Seagate Technology Holdings PLC (NASDAQ:STX) from Equal-Weight to Overweight. Seagate Tech Hldgs earned $1.81 in the third quarter, compared to $ Read more
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Read more
What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes  appeared first on Penny Stocks to Buy, Picks, News and Informat Read more

Implied Volatility Surging for Genocea (GNCA) Stock Options

12:49pm, Monday, 11'th Apr 2022 Zacks Investment Research
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately. Read more
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Read more

Genocea Biosciences to Host Investor Webinar

12:07pm, Monday, 04'th Apr 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced deta Read more

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference

09:06pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Read more

Genocea Biosciences GAAP EPS of -$0.19 misses by $0.01

12:02pm, Thursday, 10'th Mar 2022 Seeking Alpha
Genocea Biosciences press release (GNCA): Q4 GAAP EPS of -$0.19 misses by $0.01.Cash and cash equivalents of $37.1M.The company''s existing cash is sufficient to support… Read more

Earnings Scheduled For March 10, 2022

09:33am, Thursday, 10'th Mar 2022 Benzinga
Companies Reporting Before The Bell • Despegar.com (NYSE: DESP ) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares UltraShort Russell2000 (NYSE: TWM ) is expected to report earnings for its fourth quarter. • Vivid Seats (NASDAQ: SEAT ) is projected to report quarterly loss at $0.07 per share on revenue of $139.54 million. • LumiraDx (NASDAQ: LMDX ) is expected to report quarterly loss at $0.09 per share on revenue of $69.60 million. • Life Time Group Hldgs (NYSE: LTH ) is expected to report quarterly loss at $0.41 per share on revenue of $356.92 million. • ATRenew (NYSE: RERE ) is likely to report quarterly loss at $0.03 per share on revenue of $368.91 million. • FuelCell Energy (NASDAQ: FCEL ) is estimated to report quarterly loss at $0.05 per share on revenue of $26.73 million. • Zealand Pharma (NASDAQ: ZEAL ) is expected to report quarterly loss at $0.93 per share on revenue of $11.98 million. • Yatsen Holding (NYSE: YSG ) is projected to report quarterly loss at $0. Read more

Genocea Biosciences Q4 2021 Earnings Preview

04:37pm, Wednesday, 09'th Mar 2022 Seeking Alpha
Genocea Biosciences (NASDAQ:GNCA) is scheduled to announce Q4 results on Thursday, Mar. 10, before market open.Consensus EPS estimate is -$0.18 and consensus revenue estimate is $0.05M. Read more

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

10:39pm, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors Read more
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Read more
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth qua Read more
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 th at 10:40 A.M. ET. Read more

Hot Stocks To Watch:

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE